GRANTS / FUNDING
Funding for Phase 1 & 2
WP1220 has received over $3 million in grants and has had over $13 million in development dollars invested in furthering the technology and expects to spend over $2 million in the next 24 months on Phase I and Phase II clinical trials.
DRUG DISCOVERY & DEVELOPMENT
UT MD Anderson Cancer Center
Ranked in the USA as No 1 cancer treatment and research center and the leading institution in the world, drug discovery.
Moleculin Biotech, Inc.
The University of Iowa
ALS through its development partner has received approval of a Clinical Trial Authorization (CTA) request from Polish regulatory authorities and is now preparing for patients to be treated with WP1220 in its first clinical trial in Poland for the topical treatment of CTCL. This clinical trial is expected to begin in 2019.
Cutaneous T-cell Lymphoma (“CTCL”).
Additional indications could include psoriasis using improved dose and schedule regime and other inflammatory skin disease that may also benefit from inhibition of p-STAT3.